General Psychiatry - Articles - Page 171

Paxil CR: Paxil by any other name...

January 1, 2003

Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

The latest member of the “controlled-release club” is GlaxoSmithKline, with its Paxil CR. While cynics may believe that CR launches are simply efforts to prolong patent-lives and therefore profits, the reality is that CR formulations are generally better tolerated and easier to dose.

Dr. John O’Reardon on Treatment-Resistant Depression

January 1, 2003

John O'Reardon, MD

TCPR-January-2009-TMS_JohnO'ReadonMD_Headshot.png John O’Reardon, MD

Associate Professor of Psychiatry, University of Pennsylvania School of Medicine, and Medical Director, Treatment Resistant Depression Clinic.

Dr. O’Reardon, I’d like to pick your mind about your approach to treatment resistant depression. First of all, how do you define it?

Paxil CR

January 1, 2003

Dr. Richard Naimark, a psychiatrist in private practice at Chestnut Hill Counseling in Dover, New Hampshire, relates a tidbit that tempers TCR’s fairly lukewarm review of Paxil CR.